NASDAQ:COCP Cocrystal Pharma Q4 2025 Earnings Report $1.19 -0.02 (-1.65%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast Cocrystal Pharma EPS ResultsActual EPS-$0.17Consensus EPS -$0.18Beat/MissBeat by +$0.01One Year Ago EPSN/ACocrystal Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACocrystal Pharma Announcement DetailsQuarterQ4 2025Date3/31/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsCocrystal Pharma's next earnings date is estimated for Friday, November 13, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Cocrystal Pharma Earnings HeadlinesCocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and TreatmentSeptember 9, 2026 | globenewswire.comCOCP: $5 Million Private Placement with OPKO HealthAugust 20, 2026 | finance.yahoo.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.September 21 at 1:00 AM | Banyan Hill Publishing (Ad)Cocrystal Pharma strengthens board with antiviral expert appointmentAugust 19, 2026 | theglobeandmail.comCocrystal Pharma Adds Veteran Leader to Board of DirectorsAugust 18, 2026 | tipranks.comCocrystal Pharma, Inc.: Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of DirectorsAugust 17, 2026 | finanznachrichten.deSee More Cocrystal Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cocrystal Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cocrystal Pharma and other key companies, straight to your email. Email Address About Cocrystal PharmaCocrystal Pharma (NASDAQ:COCP) is a clinical-stage biotechnology company focused on developing antiviral therapeutics for serious and potentially life-threatening viral infections. The company uses structure-based drug design and other drug-discovery technologies to develop small-molecule candidates intended to target highly conserved viral replication proteins. Its development programs have focused on infections including influenza A and B, norovirus and coronaviruses. Cocrystal’s investigational pipeline has included CC-42344, an orally administered influenza A polymerase inhibitor, and programs targeting norovirus and other viral pathogens. These candidates remain under clinical or preclinical development and are not approved for commercial use. Cocrystal Pharma is based in Bothell, Washington, and has historically operated as a research-oriented biotechnology company serving global infectious-disease markets through its drug-development programs and collaborations. The company’s leadership has included Gary Wilcox as president and chief executive officer. As a clinical-stage company, Cocrystal’s operations are primarily centered on research, clinical development and potential partnering rather than the sale of marketed products.View Cocrystal Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Dividend Stocks That Combine Income, Earnings Growth, and Wall Street SupportCoach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback3 Retail Stocks Getting Crushed and the Long-Dated Options Trade on Each One3 Surging Stocks That Don’t Need the AI Boom to Keep WinningJ.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. Housing3 Software Stocks Rebounding as AI Fears Give Way to Growth Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
